News

Long-term collaborative research partnership continues to serve as successful biotechnology incubator for disruptive drug discovery and safety testing platforms and applications.

Unique packaging solution, engineered to protect delicate assay-ready 3D cell-based tissue models during express shipping, captivates judges in internationally recognized competition

Ingenious InFloat™ Shipping System protects and secures delicate microtissues in transit, ensuring they are ready to use in drug discovery and safety testing experiments upon arrival.

New program will enable academic research teams to develop applications for plug-and-play organ-on-chip technology without requiring resource intensive platform and model development

Online purchasing option for assay-ready 3D InSight™ Human Liver Microtissues to help eliminate 3D model development delays for labs ready to resume compound testing and risk assessment.

Move optimally positions InSphero to build on its business development, scientific research, and operational teams.

New study confirms hanging drop microfluidics platform for miniaturized islet perifusion assays enables high-resolution assessment of islet insulin secretion from single human islets over time.

Organizations working on new medications and vaccine formulations may request free safety testing using preclinical liver models that identify potential for toxic effects in humans.

New pricing structure will enable researchers to save close to 50% on 3D models for liver toxicology and drug safety testing applications

New R&D services platform will make it easier for researchers throughout the world to purchase InSphero assay ready models and services for drug efficacy and safety testing

InSphero received an award at the 2019 Sino-European Innovation Week in Healthcare Technology (SEIWHT) meeting held in Nanjing, China. At the event, InSphero highlighted its 3D InSight™ Human Liver Disease Discovery Platform for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), a breakthrough 3D cell technology for drug discovery and safety testing.

3D InSight™ Human Liver Disease Platform will be used to screen effects of Akero lead program AKR-001 on underlying metabolic and fibrotic drivers of NAFLD and NASH.

New platform to combine stem cell and CRISPR gene-editing technology with proven 3D cell culture techniques for producing standardized pancreatic islet disease models

In a recent study published in the Proceedings of the National Academy of Sciences (PNAS), researchers at Cyclerion Therapeutics, a clinical stage biopharmaceutical company, used InSphero 3D InSight™ Human Liver Disease Microtissue models to evaluate praliciguat, a systemic small molecule stimulator of soluble guanylate cyclase (sGC), as a potential treatment for non-alcoholic steatohepatitis (NASH) and fibrotic liver disease. Study results support further investigation of sGC stimulation as a potential therapeutic approach for NASH and fibrosis, and validate the utility of 3D InSight™ human liver disease models for preclinical drug screening.

InSphero AG today announced a breakthrough in 3D cell technology for drug discovery and safety testing with the launch of its 3D InSight™ Human Liver Disease Discovery Platform for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The platform has been precisely engineered to include all the human liver cell types and inducers necessary to replicate progression of NASH in patients, from fatty liver (steatosis) to inflammation (NASH) and scarring (fibrosis) of the liver. This game-changing preclinical discovery platform enables scalable in vitro drug efficacy assessment, screening, combinatorial testing as well as the study of complex NASH pathophysiology.